...
首页> 外文期刊>Urology >Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?
【24h】

Is there a role for periurethral collagen injection in the management of urodynamically proven mixed urinary incontinence?

机译:尿道周围胶原蛋白注射在尿动力学证实的混合性尿失禁的治疗中有作用吗?

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To investigate the effectiveness of periurethral collagen injection (PCI) in patients presenting with symptoms of mixed urinary incontinence (MUI) and urodynamically demonstrated sphincter deficiency and detrusor overactivity. METHODS: A retrospective review was performed on all patients undergoing PCI from February 1999 to February 2003, during which those with MUI were treated with PCI as first-line therapy. The inclusion criteria were MUI symptoms, detrusor overactivity on urodynamic study, stress urinary incontinence due to sphincter deficiency (determined from physical examination, stress test, urodynamic study with Valsalva leak point pressure, and cystography findings, without urethral hypermobility). The primary outcome measures were the Urogenital Distress Inventory (UDI), Incontinence Impact Questionnaire, and quality-of-life score and the need for anticholinergic medications or additional surgery. Comparisons were performed using the Wilcoxon signed ranks test and paired t test. RESULTS: Of the 56 patients who underwent PCI, 43 presented with symptoms of MUI, and 16 of these (29%) had both detrusor overactivity and stress urinary incontinence on urodynamic study. The mean follow-up after PCI (without additional PCI) was 18 months (range 6 to 39). The mean age was 65 years (range 40 to 84). The mean Valsalva leak point pressure was 54 +/- 40 cm H2O (range 18 to 146). Ten patients had undergone previous anti-incontinence procedures, and anticholinergic medications had failed in six. The questionnaire scores, indicating severe MUI/poor quality of life before PCI, improved after PCI: UDI question 1, 2.3 +/- 0.8 versus 1.3 +/- 1.0 (P = 0.021); UDI question 2, 2.1 +/- 1.2 versus 1.4 +/- 1.0 (P 0.068); UDI question 3, 2.9 +/- 0.4 versus 1.8 +/- 1.2 (P quality-of-life question, 8.6 +/- 2.1 versus 5.2 +/- 3.5 (P = 0.026). The mean injected volume/patient was 8.5 cm3 (range 5 to 17) within a mean of 1.9 treatments (range 1 to 3). Four patients continued taking anticholinergic medications and one proceeded to sling placement. CONCLUSIONS: The use of PCI as the primary/initial intervention in patients with MUI may be the preferred approach, particularly in patients with an elevated risk of anticholinergic medication side effects or when voiding dynamics preclude sling placement.
机译:目的:研究尿道周围胶原蛋白注射(PCI)在出现混合性尿失禁(MUI)症状,尿动力学检查证明括约肌缺乏和逼尿肌过度活动的患者中的有效性。方法:对1999年2月至2003年2月期间所有接受PCI的患者进行回顾性研究,在此期间,MUI患者接受PCI作为一线治疗。纳入标准包括MUI症状,尿动力学研究中逼尿肌过度活动,括约肌缺乏导致的压力性尿失禁(由体格检查,压力测试,具有Valsalva泄漏点压力的尿动力学研究以及无尿道过度活动的膀胱造影发现)。主要结局指标包括泌尿生殖器窘迫量表(UDI),失禁影响问卷,生活质量评分以及是否需要抗胆碱药或其他手术治疗。使用Wilcoxon符号秩检验和配对t检验进行比较。结果:在接受PCI的56例患者中,有43例出现MUI症状,其中16例(29%)在尿流动力学研究中均出现逼尿肌过度活动和压力性尿失禁。 PCI(无额外PCI)后的平均随访时间为18个月(范围6至39)。平均年龄为65岁(范围为40到84)。 Valsalva的平均泄漏点压力为54 +/- 40 cm H2O(范围为18至146)。十名患者接受过先前的抗失禁程序,其中六种患者的抗胆碱能药物无效。问卷评分表明PCI前严重的MUI /生活质量较差,PCI后有所改善:UDI问题1,2.3 +/- 0.8对1.3 +/- 1.0(P = 0.021); UDI问题2:2.1 +/- 1.2与1.4 +/- 1.0(P 0.068); UDI问题3,2.9 +/- 0.4与1.8 +/- 1.2(P生活质量问题,8.6 +/- 2.1与5.2 +/- 3.5(P = 0.026)。平均注射量/患者为8.5 cm3 (范围5至17),平均1.9次治疗(范围1至3);四名患者继续服用抗胆碱药,另一名患者继续悬吊放置结论:将PCI作为MUI患者的主要/初始干预措施可能是首选方法,尤其是在抗胆碱能药物副作用风险较高的患者中,或者由于排尿动力学而无法放置吊带时。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号